Skip to main content

Table 6 Side-effects of first-line afatinib

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

CTCAE grade

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

Diarrhea, No. (%)

39 (45.9)

25 (29.4)

17 (20.0)

4 (4.7)

0

Stomatitis, No. (%)

62 (72.9)

13 (15.3)

8 (9.4)

2 (2.4)

0

Acne/rash, No. (%)

25 (29.4)

35 (41.2)

20 (23.5)

5 (5.9)

0

Paronychia, No. (%)

51 (60.0)

23 (27.1)

8 (9.4)

3 (3.5)

0

Fatigue, No. (%)

71 (83.5)

13 (15.3)

1 (1.2)

0

0

Side-effects, No (%)

17 (20.0)

59 (69.4)

9 (10.6)

  1. Abbreviations: CTCAE Common Terminology Criteria for Adverse Events